Biotec Services International, a company that works on behalf of global pharmaceutical companies, has expanded its team of registered qualified persons to help meet demand for its pharmaceutical services.
New consultants Dr Ken Caldicott and Alan Smith join the team as consultants, expanding the team from three to five people. The company's recent expansions into the USA, Canada and Israel have seen the demand for Biotec's services increasing rapidly and with that the need for the expertise of more qualified persons.
Caldicott is a chartered chemist and Fellow of the Royal Society of Chemistry, who has over 35 years experience in the pharmaceutical sector. He now operates his own consultancy business, providing QP and CMC regulatory and strategy advice to many international clients, including Japan and the US and can offer Biotec's clients advice on CMC strategy for clinical trials supplies.
Smith - also a chartered chemist with extensive quality and business experience within the pharmaceutical industry - has worked for a series of international companies including Glaxo Smith Kline.
During Alan's 20 years of experience he has initiated a new cytotoxic production facility resulting in successful MCA and FDA inspections, he has project managed the transfer of key products to external manufacturers and has established a quality and compliance index that led to a significant improvement in inspection readiness status in one year.
"Biotec will greatly benefit from both Alan and Ken's extensive and impressive knowledge and experience and we are very pleased to have them both as part of the team," said Biotec MD Marc Weinzweig.
Sarah Coram also joins as the company as operations manager, a position recently created as a result of the increased volume of clinical trials being handled at Biotec and Jeremy Martin moves to the newly created role of Planning Manager in order to plan and schedule the import, labelling, assembly and logistics operations.
Weinzweig added: "The expansion of our QP team and the newly created position of operations manager and planning manager for Sarah and Jeremy marks a significant move for Biotec. The company is growing rapidly with the demand for our clinical trial services. We are currently running in excess of 80 clinical trials for our clients, but with Alan, Ken, Sarah and Jeremy onboard and our new state of the art facilities we will be able to take on a great deal more."
Weinzweig has ambitious plans aimed at making Biotec one of the largest pharmaceutical out-sourcing companies specialising in temperature sensitive pharmaceutical drug trials in Europe.